Prevention of Postoperative Events following Reversal with Sugammadex or Neostigmine (the P-PERSoN Trial): Pilot Data Following Early Termination of a Prospective, Blinded, Randomised Trial
Table 3
Outcome data.
Sugammadex
Neostigmine
value
Postoperative pulmonary complication
0 (0–17)%
9 (0–41)%
0.37
PONV score > 1
16 (3–40)%
10 (0–44)%
0.99
Events in PACU (%)
16 (3–40)%
27 (6–60)%
0.59
QOR-15 Day 1
102 (88–116)
87 (60–104)
0.21
QoR-15 Day-30
129 (117–142)
133 (120–146)
0.61
Need for postoperative antibiotics to day 30
6 (0–29)%
0 (0–28)%
0.99
Need for new or increased bronchodilators to day 30
0 (0–19)%
0 (0–28)%
0.99
Hospital discharge summary diagnosis of respiratory infection
0 (0–18)%
0 (0–28)%
0.99
Hospital length of stay (days)
4.2 (2.8–5.6)
5.6 (2.2–9.0)
0.44
PONV, postoperative nausea and vomiting, QoR-15, quality of recovery-15 score, PACU, postanaesthetic care unit). data presented as n (95% CI).
